Trial Profile
An Open-label, Prospective, Multicentre, Uncontrolled, Proof of Concept Study Assessing the Efficacy of Lucentis (Ranibizumab) Administered by an Individualized "Treat and Extend" Dosing Regimen in Patients With Visual Impairment Due to Diabetic Macular Edema.
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 01 Mar 2017
Price :
$35
*
At a glance
- Drugs Ranibizumab (Primary)
- Indications Diabetic macular oedema
- Focus Therapeutic Use
- Acronyms OPTIMAL
- 27 Aug 2013 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 27 Apr 2012 Actual initiation date (1 Aug 2011) added as reported by ClinicalTrials.gov.
- 27 Apr 2012 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.